首页> 外文期刊>Tumour biology : >Conjugation of gold nanoparticles and recombinant human endostatin modulates vascular normalization via interruption of anterior gradient 2–mediated angiogenesis
【24h】

Conjugation of gold nanoparticles and recombinant human endostatin modulates vascular normalization via interruption of anterior gradient 2–mediated angiogenesis

机译:金纳米粒子和重组人内皮抑素的结合通过中断前梯度2介导的血管生成来调节血管正常化

获取原文
获取外文期刊封面目录资料

摘要

Several studies have revealed the potential of normalizing tumor vessels in anti-angiogenic treatment. Recombinant human endostatin is an anti-angiogenic agent which has been applied in clinical tumor treatment. Our previous research indicated that gold nanoparticles could be a nanoparticle carrier for recombinant human endostatin delivery. The recombinant human endostatin–gold nanoparticle conjugates normalized vessels, which improved chemotherapy. However, the mechanism of recombinant human endostatin–gold nanoparticle–induced vascular normalization has not been explored. Anterior gradient 2 has been reported to be over-expressed in many malignant tumors and involved in tumor angiogenesis. To date, the precise efficacy of recombinant human endostatin–gold nanoparticles on anterior gradient 2–mediated angiogenesis or anterior gradient 2–related signaling cohort remained unknown. In this study, we aimed to explore whether recombinant human endostatin–gold nanoparticles could normalize vessels in metastatic colorectal cancer xenografts, and we further elucidated whether recombinant human endostatin–gold nanoparticles could interrupt anterior gradient 2–induced angiogenesis. In vivo, it was indicated that recombinant human endostatin–gold nanoparticles increased pericyte expression while inhibit vascular endothelial growth factor receptor 2 and anterior gradient 2 expression in metastatic colorectal cancer xenografts. In vitro, we uncovered that recombinant human endostatin–gold nanoparticles reduced cell migration and tube formation induced by anterior gradient 2 in human umbilical vein endothelial cells. Treatment with recombinant human endostatin–gold nanoparticles attenuated anterior gradient 2–mediated activation of MMP2, cMyc, VE-cadherin, phosphorylation of p38, and extracellular signal–regulated protein kinases 1 and 2 (ERK1/2) in human umbilical vein endothelial cells. Our findings demonstrated recombinant human endostatin–gold nanoparticles might normalize vessels by interfering anterior gradient 2–mediated angiogenesis in metastatic colorectal cancer.
机译:几项研究揭示了在抗血管生成治疗中使肿瘤血管正常化的潜力。重组人内皮抑素是一种已在临床肿瘤治疗中应用的抗血管生成剂。我们先前的研究表明,金纳米颗粒可能是重组人内皮抑素递送的纳米颗粒载体。重组人内皮抑素-金纳米颗粒结合了标准化的血管,从而改善了化疗。但是,尚未研究重组人内皮抑素-金纳米颗粒诱导的血管正常化的机制。据报道,前梯度2在许多恶性肿瘤中过表达,并参与肿瘤血管生成。迄今为止,重组人内皮抑素-金纳米颗粒对前梯度2介导的血管生成或前梯度2相关的信号转导队列的确切疗效尚不清楚。在这项研究中,我们旨在探讨重组人内皮抑素-金纳米颗粒是否可以使转移性结直肠癌异种移植物中的血管正常化,并且我们进一步阐明重组人内皮抑素-金纳米颗粒是否可以中断前梯度2诱导的血管生成。在体内,这表明重组人内皮抑素-金纳米颗粒在转移性结直肠癌异种移植物中可增加周细胞表达,同时抑制血管内皮生长因子受体2和前梯度2表达。在体外,我们发现重组人内皮抑素-金纳米颗粒减少了人脐静脉内皮细胞中前梯度2诱导的细胞迁移和管形成。重组人内皮抑素-金纳米颗粒的治疗减弱了人脐静脉内皮细胞中MMP2,cMyc,VE-钙黏着蛋白的前梯度2介导的激活,p38的磷酸化以及细胞外信号调节蛋白激酶1和2(ERK1 / 2)的作用。我们的研究结果表明,重组人内皮抑素-金纳米颗粒可能通过干扰转移性结直肠癌中前梯度2介导的血管生成而使血管正常化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号